Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy

Mário Lima-Fontes; Mariana Leuzinger-Dias; Ricardo Barros-Pereira; Vítor Fernandes; Manuel Falcão; Fernando Falcão-Reis; Amândio Rocha-Sousa; Pedro Alves-Faria

doi:10.1007/s40123-022-00613-9

Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy

Ophthalmol Ther. 2023 Feb;12(1):377-388. doi: 10.1007/s40123-022-00613-9. Epub 2022 Nov 21.

Authors

Mário Lima-Fontes^{1

2}, Mariana Leuzinger-Dias³, Ricardo Barros-Pereira³, Vítor Fernandes³, Manuel Falcão^{3

4}, Fernando Falcão-Reis^{3

4}, Amândio Rocha-Sousa^{3

4}, Pedro Alves-Faria^{3

4}

Affiliations

¹ Department of Ophthalmology, Centro Hospitalar Universitário São João, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal. marioruifontes@gmail.com.
² Department of Biomedicine, Faculty of Medicine, University of Porto, Porto, Portugal. marioruifontes@gmail.com.
³ Department of Ophthalmology, Centro Hospitalar Universitário São João, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal.
⁴ Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal.

Abstract

Introduction: Postoperative cystoid macular edema (PCME) is a complication of several ocular procedures, including pars plana vitrectomy (PPV), due to the activation of the inflammatory cascade. The purpose of this case series is to evaluate the effectiveness and safety of fluocinolone acetonide intravitreal implant (FAc, 0.2 μg/day; ILUVIEN®) in the treatment of refractory PCME after successful PPV.

Methods: This retrospective observational case series includes consecutive eyes of patients with recurrent PCME after PPV and treated with a single FAc implant at Centro Hospitalar Universitário de São João, Porto, Portugal. Previous treatments, best-corrected visual acuity (BCVA, ETDRS letters), central macular thickness (CMT, μm), intraocular pressure (IOP, mmHg), and IOP-lowering medication needed were recorded at baseline and during follow-up. Total macular edema resolution was defined as CMT less than 300 μm or a reduction of greater than 20%, and partial macular edema resolution was defined as a reduction of greater than 10%.

Results: Nine eyes from nine patients were included. Before FAc implant, all eyes received intravitreal short-action corticosteroids (triamcinolone and dexamethasone implant), with a good response but relapse 1-5 months later. At baseline, BCVA was 55.0 ± 10.6 letters, CMT was 514.9 ± 165.6 μm, and IOP was 15.4 ± 2.4 mmHg with four eyes under IOP-lowering medication. After FAc implant, all eyes achieved edema resolution (eight total and one partial) with a peak gain of 17.2 letters and a maximum decrease of 208.2 μm in CMT. During follow-up (44.0 ± 14.8 months), 66.7% of the eyes kept their macula dry and three showed recurrence after 11, 14, and 28 months, respectively. The maximum IOP registered was 17.0 ± 6.0 mmHg. IOP-lowering regimen was increased in one eye and two additional eyes started hypotensive drops.

Conclusion: FAc implant can be considered a therapeutic alternative in PCME refractory to other therapies in vitrectomized eyes, reducing the need for repeated treatments.

Keywords: Fluocinolone acetonide implant; Pars plana vitrectomy; Recurrent cystoid macular edema.